ClinicalTrials.gg
CompletedNCT02867709ACHIEVE IIUpdated Mar 19, 2019Results posted

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

A Phase 3 interventional study of Ubrogepant and Placebo-matching Ubrogepant in Migraine, With or Without Aura, sponsored by Allergan. Completed at 109 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,686
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Enrollment
Largest of 14
1,686 · median 507
Started
2016
with 2 others
Phase 3
7 of 14
2 open now
Registered
4th of 14
by date
Lead sponsor
6 of 14
Allergan

Among the 14 studies testing ubrogepant in Migraine Disorders, this one has the largest enrollment, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 4th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.

03

Conditions studied

  • Migraine, With or Without Aura

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, beta version
  • Migraine onset before age 50
  • History of migraines typically lasting between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
  • History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the previous 3 months.

Exclusion criteria

Exclusion Criteria:

  • Difficulty distinguishing migraine headache from tension-type other headaches
  • Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per month in the previous 3 months
  • Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
  • Required hospital treatment of a migraine attack 3 or more times in the previous 6 months
  • Has a chronic non-headache pain condition requiring daily pain medication
  • Has a history of in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • Has a history of any prior gastrointestinal conditions (eg, diarrhoea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of product; participants with prior gastric bariatric interventions which have been reversed are not excluded
  • Has a history of hepatitis within previous 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,686 participants (actual)

Study arms

  • Experimental
    Ubrogepant 25 mg

    1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.

    Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant

  • Experimental
    Ubrogepant 50 mg

    1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.

    Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant

  • Placebo comparator
    Placebo

    1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.

    Drug: Placebo-matching Ubrogepant

Interventions

  • Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

  • DrugPlacebo-matching Ubrogepant

    Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose

    Pain freedom was defined as a reduction in headache pain severity from moderate/severe at baseline to no pain at 2 hours after the initial dose of investigational product. Participants were provided with electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.

    Time frame: Baseline (Predose) to 2 hours after initial dose

  2. Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose

    The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms assessed.

    Time frame: Baseline (Predose) to 2 hours after initial dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose

    Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.

    Time frame: Baseline (Predose) to 2 hours after initial dose

  2. Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose

    Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain relief from 2 to 24 hours after initial dose.

    Time frame: 2 to 24 hours after initial dose

  3. Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose

    Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain freedom from 2 to 24 hours after initial dose.

    Time frame: 2 to 24 hours after initial dose

  4. Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose

    Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.

    Time frame: 2 hours after initial dose

  5. Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose

    Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.

    Time frame: 2 hours after initial dose

  6. Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose

    Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.

    Time frame: 2 hours after initial dose

07

Results

Posted Jan 29, 2019

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlaceboUbrogepant 25 mgUbrogepant 50 mg
Started563561562
Safety population: received study drug499478488
Completed493474487
Not completed708775
Withdrew: Adverse event112
Withdrew: Withdrawal of consent798
Withdrew: Lost to follow-up172020
Withdrew: Lack of qualifying event425542
Withdrew: Protocol violation323
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestonePlaceboUbrogepant 25 mgUbrogepant 50 mg
Started493474487
Completed482459473
Not completed111514
Withdrew: Withdrawal of consent186
Withdrew: Lost to follow-up1057
Withdrew: Pregnancy010
Withdrew: Protocol violation011

Outcome measures

PrimaryPercentage of Participants With Pain Freedom at 2 Hours After Initial Dose

Pain freedom was defined as a reduction in headache pain severity from moderate/severe at baseline to no pain at 2 hours after the initial dose of investigational product. Participants were provided with electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.

Time frame:
Baseline (Predose) to 2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose14.320.721.8
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.0285 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.56 · 95% CI 1.09 to 2.22Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0129 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.62 · 95% CI 1.14 to 2.29Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
PrimaryPercentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose

The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms assessed.

Time frame:
Baseline (Predose) to 2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose27.434.138.9
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.0711 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.37 · 95% CI 1.02 to 1.83Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, underlying symptom as explanatory variables.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0129 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.65 · 95% CI 1.25 to 2.20Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, underlying symptom as explanatory variables.
SecondaryPercentage of Participants With Pain Relief at 2 Hours After the Initial Dose

Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.

Time frame:
Baseline (Predose) to 2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose48.260.562.7
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.0711 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.65 · 95% CI 1.25 to 2.17Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0129 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.77 · 95% CI 1.35 to 2.32Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose

Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain relief from 2 to 24 hours after initial dose.

Time frame:
2 to 24 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose21.032.536.7
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.0711 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.82 · 95% CI 1.33 to 2.48Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0129 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 2.16 · 95% CI 1.59 to 2.92Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose

Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain freedom from 2 to 24 hours after initial dose.

Time frame:
2 to 24 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose8.212.714.4
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.0711 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.62 · 95% CI 1.04 to 2.53Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0129 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.85 · 95% CI 1.20 to 2.83Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
SecondaryPercentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose

Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.

Time frame:
2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose35.539.343.8
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.1833 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.28 · 95% CI 0.96 to 1.72Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, photophobia were explanatory variables.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0167 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.52 · 95% CI 1.14 to 2.02Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, photophobia were explanatory variables.
SecondaryPercentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose

Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.

Time frame:
2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose46.353.654.1
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.1066 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.38 · 95% CI 1.04 to 1.83Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, phonophobia were explanatory variables.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0440 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.39 · 95% CI 1.05 to 1.84Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, phonophobia were explanatory variables.
SecondaryPercentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose

Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.

Time frame:
2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 25 mgUbrogepant 50 mg
Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose70.070.671.3
Statistical analysis
  • Placebo vs Ubrogepant 25 mg · Regression, Logistic · p = 0.9522 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.10 · 95% CI 0.81 to 1.49Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, nausea were explanatory variables.
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.9522 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.12 · 95% CI 0.83 to 1.51Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, nausea were explanatory variables.

Adverse events

Collected over From first dose through 30 days after the last dose of study drug (approximately 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/499 (0%)0/499 (0%)0/499 (0%)
Ubrogepant 25 mg0/478 (0%)1/478 (0.2%)0/478 (0%)
Ubrogepant 50 mg0/488 (0%)0/488 (0%)0/488 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboUbrogepant 25 mgUbrogepant 50 mg
Ligament sprainInjury, poisoning and procedural complications0/4991/4780/488
Loss of consciousnessNervous system disorders0/4991/4780/488
Renal haematomaRenal and urinary disorders0/4991/4780/488
Road traffic accidentInjury, poisoning and procedural complications0/4991/4780/488
Splenic ruptureInjury, poisoning and procedural complications0/4991/4780/488
SyncopeNervous system disorders0/4991/4780/488
Traumatic renal injuryInjury, poisoning and procedural complications0/4991/4780/488

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboUbrogepant 25 mgUbrogepant 50 mgTotal
Mean41.5 ± 12.241.6 ± 12.341.0 ± 12.441.4 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUbrogepant 25 mgUbrogepant 50 mgTotal
Female4945014971492
Male696065194
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUbrogepant 25 mgUbrogepant 50 mgTotal
White4494674561372
Black or African American948293269
Asian86519
American Indian or Alaska Native4149
Native Hawaiian/Other Pacific Islander1113
Multiple74314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUbrogepant 25 mgUbrogepant 50 mgTotal
Hispanic or Latino116129125370
Not Hispanic or Latino4474324371316
08

Study locations

109 sites
  • Clinical Research Advantage, Inc./Simon Williamson Clinic
    Birmingham, Alabama 35211, United States
  • Clinical Research Advantage, Inc./East Valley Family Physicians, PLC
    Chandler, Arizona 85224, United States
  • St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI)
    Phoenix, Arizona 85013, United States
  • Clinical Research Advantage, Inc./Central Phoenix Medical Clinic, LLC
    Phoenix, Arizona 85020, United States
  • Mayo Clinic Arizona, May Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Radiant Research Inc.
    Tucson, Arizona 85712, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Axiom Research, LLC
    Apple Valley, California 92307, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Axiom Research, LLC
    Colton, California 92324, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • California Headache and Balance Center
    Fresno, California 93720, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Grossmont Center For Clinical Research
    La Mesa, California 91942, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • California Advanced Neurotherapeutic, Inc.
    Los Angeles, California 90024, United States
  • Cedars Sinai Pain Center
    Los Angeles, California 90048, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • Desert Valley Research
    Rancho Mirage, California 92270, United States
  • George J Rederich MD, Inc
    Redondo Beach, California 90277, United States
  • Artemis Institute For Clinical Research
    San Diego, California 92103, United States
  • Clinical Research Advantage, Inc./Cassidy Medical Group-Vista
    Vista, California 92083, United States
  • Clinicos, LLC
    Colorado Springs, Colorado 80904, United States
  • Colorado Neurological Institute
    Englewood, Colorado 80113, United States
  • Advanced Neurosciences Research, LLC
    Fort Collins, Colorado 80528, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Radiant Clinical Research
    Washington, District of Columbia 20016, United States
  • Aventura Neurological Associates
    Aventura, Florida 33180, United States
  • Clinical Research South Florida
    Coral Gables, Florida 33134, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Broward Research Group
    Hollywood, Florida 33024, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Neurology Associates, P.A.
    Maitland, Florida 32751, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • LCC Medical Research Institute, LLC
    Miami, Florida 33126, United States
  • Well Pharma Medical Research, Corp.
    Miami, Florida 33143, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Sensible Healthcare, LLC
    Ocoee, Florida 34761, United States
  • QPS MRA, LLC (Miami Research Associates)
    South Miami, Florida 33143, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • The Kaufmann Clinic, Inc.
    Atlanta, Georgia 30308, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Clinical Research Advantage, Inc./Michigan Avenue Internists
    Chicago, Illinois 60604, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Robbins Headache Clinic
    Riverwoods, Illinois 60015, United States
  • Josephson Wallack Munshower Neurology P.C.
    Indianapolis, Indiana 46256, United States
  • Norton Neurology Services MS Services
    Louisville, Kentucky 40207, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Seton Medical Group
    Baltimore, Maryland 21228, United States
  • Overlea Personal Physicians
    Baltimore, Maryland 21236, United States
  • BTC of New Bedford
    New Bedford, Massachusetts 02740, United States
  • Beacon Clinical Research, LLC
    Quincy, Massachusetts 02169, United States
  • New England Regional Headache Center, Inc.
    Worcester, Massachusetts 01605, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Minneapolis Clinic of Neurology
    Golden Valley, Minnesota 55422, United States
  • The Headache Center
    Ridgeland, Mississippi 39157, United States
  • Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
    Fremont, Nebraska 68025, United States
  • Clinical Research Advantage, Inc
    Omaha, Nebraska 68114, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Hope Research Institute
    Las Vegas, Nevada 89106, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Princeton Center for Clinical Research
    Skillman, New Jersey 08558, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • DENT Neurosciences Research Center
    Amherst, New York 14226, United States
  • Cushing Neuroscience Institute North Shore-LIJ Medical Group
    Great Neck, New York 11021, United States
  • ProHealth Care Associates, LLP
    Plainview, New York 11803, United States
  • Upstate Clinical Research Associates, LLC
    Williamsville, New York 14221, United States
  • Westchester Neuro. Const
    Yonkers, New York 10701, United States
  • Carolina Headache Institute
    Durham, North Carolina 27713, United States
  • Headache Wellness Center, PC
    Greensboro, North Carolina 27405, United States
  • Lake Shore Clinical Research, LLC
    Mooresville, North Carolina 28117, United States
  • Raleigh Neurology Associates, PA
    Raleigh, North Carolina 27607, United States
  • Plains Clinical Research Center, LLC
    Fargo, North Dakota 58104, United States
  • Radiant Research, Inc.
    Akron, Ohio 44311, United States
  • Sentral Clinical Research Services
    Cincinnati, Ohio 45212, United States
  • Patient Priority Clinical Sites, LLC
    Cincinnati, Ohio 45215, United States
  • University of Cincinnati Dept of Psychiatry & Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45227, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • Preferred Primary Care Physicians, Inc.
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Abington Neurological Associates, Ltd.
    Willow Grove, Pennsylvania 19090, United States
  • Radiant Research, Inc.
    Anderson, South Carolina 29621, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Vista Clinical Research
    Columbia, South Carolina 29201, United States
  • Hillcrest Clinical Research, LLC
    Simpsonville, South Carolina 29681, United States
  • Middle Tennessee Clinical Research
    Fayetteville, Tennessee 37334, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Baptist Memorial Medical Group (Neurology Specialist - Headache Clinic)
    Memphis, Tennessee 38120, United States
  • Texas Neurology, P.A.
    Dallas, Texas 75214, United States
  • Radiant Research, Inc
    Dallas, Texas 75234, United States
  • Research Trials Worldwide, LLC
    Humble, Texas 77338, United States
  • Advanced Research Institute
    Ogden, Utah 84403, United States

Showing the first 100 of 109 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Johnston KM, Powell L, Popoff E, Harris L, Croop R, Coric V, L'Italien G. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. Clin J Pain. 2022 Nov 1;38(11):680-685. doi: 10.1097/AJP.0000000000001072. PubMed 36125279 ↗
  • Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE, Dodick DW. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022 Apr 25;23(1):50. doi: 10.1186/s10194-022-01419-7. PubMed 35468729 ↗
  • Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Adv Ther. 2022 Jan;39(1):692-705. doi: 10.1007/s12325-021-01923-3. Epub 2021 Dec 7. PubMed 34874514 ↗
  • Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021 Aug;41(9):979-990. doi: 10.1177/03331024211000311. Epub 2021 Apr 19. PubMed 33874756 ↗
  • Hutchinson S, Dodick DW, Treppendahl C, Bennett NL, Yu SY, Guo H, Trugman JM. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. Neurol Ther. 2021 Jun;10(1):235-249. doi: 10.1007/s40120-021-00234-7. Epub 2021 Feb 20. PubMed 33608814 ↗
  • Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, M Adams A, Jakate A, Liu C, Szegedi A, Trugman JM. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. Cephalalgia. 2021 Apr;41(5):546-560. doi: 10.1177/0333102420970523. Epub 2020 Nov 26. PubMed 33241721 ↗
  • Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019 Nov 19;322(19):1887-1898. doi: 10.1001/jama.2019.16711. Erratum In: JAMA. 2020 Apr 7;323(13):1318. doi: 10.1001/jama.2020.3217. PubMed 31742631 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jan 2018, 16 months.

Results were first posted in Jan 2019, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2016
First posted
Aug 16, 2016
StartActual
Aug 26, 2016
Primary completionActual
Jan 25, 2018
CompletionActual
Feb 26, 2018
Results first posted
Jan 29, 2019
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02867709
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Aug 16, 2016
Start date
Aug 26, 2016
Primary completion
Jan 25, 2018
Completion
Feb 26, 2018
Results posted
Jan 29, 2019
Last update
Mar 19, 2019

Study contacts

Adele Thorpe
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion